Firefly Neuroscience
Firefly Neuroscience is revolutionizing brain health assessments with its FDA-cleared Brain Network Analytics (BNA™) platform. BNA™ leverages advanced AI and a proprietary EEG database of over 17,000 individuals to provide objective, data-driven evaluations of brain function. The technology analyzes Event-Related Potentials (ERPs), spectral EEG, and behavioral data to assist physicians in diagnosing and managing neurological and psychiatric conditions, including ADHD, depression, Alzheimer's, and Parkinson's disease. By offering quantifiable insights, BNA™ aims to improve patient outcomes and operational efficiency for healthcare professionals. Firefly's business model appears to be B2B SaaS for healthcare providers, with potential for companion diagnostics in CNS drug development. The company has achieved significant regulatory milestones, including FDA Class II medical device 510(k) clearance and CE mark approval.
Firefly Neuroscience
Firefly Neuroscience is revolutionizing brain health assessments with its FDA-cleared Brain Network Analytics (BNA™) platform. BNA™ leverages advanced AI and a proprietary EEG database of over 17,000 individuals to provide objective, data-driven evaluations of brain function. The technology analyzes Event-Related Potentials (ERPs), spectral EEG, and behavioral data to assist physicians in diagnosing and managing neurological and psychiatric conditions, including ADHD, depression, Alzheimer's, and Parkinson's disease. By offering quantifiable insights, BNA™ aims to improve patient outcomes and operational efficiency for healthcare professionals. Firefly's business model appears to be B2B SaaS for healthcare providers, with potential for companion diagnostics in CNS drug development. The company has achieved significant regulatory milestones, including FDA Class II medical device 510(k) clearance and CE mark approval.